020 7713 0990

The aim of this guideline is to provide recommendations to clinicians in relation to testing for heritable thrombophilia in the context of clinical management of venous thrombosis and pregnancy morbidity. This guideline is restricted to heritable thrombophilias shown to be associated with at least a two-fold increased risk of venous thrombosis, namely deficiencies of antithrombin, protein C and protein S due to mutations in the corresponding genes SERPINC1, PROC, PROS1 and the two common mutations F5G1691A (FV R506Q, factor V Leiden) andF2G20210A (commonly referred to as the prothrombin gene mutation).

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.